Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI

Key Points

• Dimensional Fund Advisors reduced its OmniAb stake by 18.9% in the first quarter, selling 407,345 shares. It still held 1.75 million shares worth approximately $2.74 million, representing a 1.21% ownership stake.
• OmniAb reported quarterly adjusted losses of $0.05 per share, beating the $0.12 loss analysts expected, while revenue of $13.41 million exceeded the $4.69 million consensus estimate. However, the company remained unprofitable, with a negative net margin of 115.12%.
• Shares opened at $3.43, near the company’s 52-week high of $3.64, and institutional investors collectively own 72.08% of the stock. Analyst sentiment is mixed, resulting in a consensus rating of Hold.

Dimensional Fund Advisors LP reduced its position in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) by 18.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,745,248 shares of the company's stock after selling 407,345 shares during the quarter. Dimensional Fund Advisors LP owned 1.21% of OmniAb worth $2,740,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its stake in shares of OmniAb by 20.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company's stock worth $78,000 after purchasing an additional 7,624 shares during the last quarter. Rhumbline Advisers lifted its stake in OmniAb by 6.0% in the 2nd quarter. Rhumbline Advisers now owns 160,728 shares of the company's stock valued at $280,000 after purchasing an additional 9,163 shares during the last quarter. Osaic Holdings Inc. grew its holdings in OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock worth $25,000 after purchasing an additional 9,716 shares during the period. AQR Capital Management LLC bought a new position in OmniAb during the first quarter worth about $25,000. Finally, BNP Paribas Financial Markets increased its position in OmniAb by 92.5% during the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company's stock worth $35,000 after buying an additional 10,438 shares during the last quarter. Institutional investors and hedge funds own 72.08% of the company's stock.

OmniAb Price Performance

NASDAQ:OABI opened at $3.43 on Friday. The company has a market cap of $496.60 million, a P/E ratio of -9.53 and a beta of 0.45. The firm's fifty day moving average price is $2.33 and its two-hundred day moving average price is $2.00. OmniAb, Inc. has a one year low of $1.30 and a one year high of $3.64.

OmniAb (NASDAQ:OABI - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.07. The company had revenue of $13.41 million during the quarter, compared to analysts' expectations of $4.69 million. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.59%. As a group, equities research analysts expect that OmniAb, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered OmniAb from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, OmniAb presently has a consensus rating of "Hold".

OmniAb Profile

OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source